Leading The Way In Pediatric Endo-Cannabinoid Medicine
Phyto Therapeutic Medicine for Inflammatory Conditions
Initial 2.2 Million Square Feet of Cultivation
Exclusive Clinically Validated Formulations
Innovation in Skin Care and Anti-Aging Systems
Relevium’s CEO Provides an Open Shareholder Letter for 2020
by Olga Tkach | December 19, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide an open letter to its shareholders from the company’s Chief Executive Officer, Aurelio...Relevium Launches LeefyLyfe™ Organic Hemp Products in the US
by Olga Tkach | November 20, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of LeefyLyfeTM Organics, a comprehensive line of organic health and wellness...Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company
by Olga Tkach | November 8, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract...Relevium Technologies
Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.contact us
Relevium Technologies Inc.
1000 Sherbrooke West, Suite 2700
Montreal, QC, H3A 3G4
(888) 528-8687
www.releviumtechnologies.com
info@releviumtechnologies.com
trading information
Market data is delayed by 15 minutes
Relevium Announces the Passing of Dr. Tina Sampalis, Director and Scientific Officer
by Olga Tkach | March 4, 2020 | 2020 Press Releases | 0 Comments
MONTREAL, March 04, 2020 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is announces the passing of Dr. Tina Sampalis, Director and Scientific Officer of the Company. It is with heavy...Relevium Ships First Purchase Order Release of $130,000 to Middle East Customer
by Olga Tkach | March 3, 2020 | 2020 Press Releases | 0 Comments
MONTREAL, March 03, 2020 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the Company’s subsidiary, BGX E-Health LLC (“BGX”), has shipped a total of CAD $130,000...Relevium Reports Improved Financial Results for Second Quarter of Fiscal 2020
by Olga Tkach | March 2, 2020 | 2020 Press Releases | 0 Comments
MONTREAL, March 02, 2020 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal year ending June 30, 2020. Financial highlights for the...